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During mammalian pregnancy, highly specialized mechanisms of immune tolerance are
triggered in order to allow the semi-allogeneic fetus to grow within the maternal uterus in
harmony with the maternal immune system. Among other mechanisms, changes in the
endocrine status have been proposed to be at least part of the machinery responsible for
the induction of immune tolerance during pregnancy. Indeed, pregnancy-associated hor-
mones, estradiol, progesterone, and human chorionic gonadotropin are known to confer
immune suppressive capacity to innate as well as adaptive immune cells. Regulatory B
cells, a subpopulation of B lymphocytes with strong immunosuppressive functions, were
shown to expand during pregnancy. Furthermore, it is well-known that some women suffer-
ing from multiple sclerosis, significantly improve their symptoms during pregnancy and this
was attributed to the effect of female sex hormones. Accordingly, estradiol protects mice
from developing experimental autoimmune encephalomyelitis by triggering the expansion
and activation of regulatory B cells. In this review, we discuss different mechanisms asso-
ciated with the development, activation, and function of regulatory B cells with a special
focus on those involving pregnancy-associated hormones.
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INTRODUCTION
Pregnancy in mammals is accompanied by profound changes and
adaptations in the endocrine as well as the immune systems. These
adaptations are necessary to allow the semi-allogeneic fetus to
grow within the maternal uterus. However, in some cases, they
may influence the course of pre-existing pathologies, as for the case
of autoimmune diseases. In this regard, it is known that women
suffering from a pre-existing autoimmune disease demonstrate
changes in disease expression during pregnancy and this has been
associated with changes in female sex hormones.
Early in pregnancy, just after conception has taken place, a sys-
temic rise of progesterone (P4) and estradiol (E2) levels produced
by corpora lutea (CL) in the ovary is evidenced. These hormones
promote modifications of the uterine epithelium that allow a
proper interaction with the blastocyst ensuring embryo implanta-
tion. Once the embryo is implanted, trophoblast cells produce and
secrete increasing levels of human chorionic gonadotropin (hCG),
which on the one side stimulates the CLs to continue producing
progesterone, estradiol (E2), and estrone (E1) (1) and on the other
side promotes angiogenesis in the uterine endothelium (2) as well
as trophoblast migration and invasion into the uterine wall (3).
Besides these widely accepted functions of female sex hormones
in coordinating and controlling anatomical modifications asso-
ciated with gravity, abundant evidence has also highlighted their
role in shaping immune cells toward a transient state of tolerance
necessary for the maintenance of pregnancy (4).
Indeed, a major challenge faced by the maternal immune sys-
tem during pregnancy is precisely one of the most important
immunological riddles. The mother’s immune system has to accept
a semi-allogeneic fetus expressing foreign antigens through a state
of immunological tolerance. At the same time, the mother and the
fetus should be properly protected against the threat of infections.
To achieve this, the immune machinery must be strictly regulated
during the different stages of pregnancy. Several cell types with
regulatory capacities have been described among T cells and B
cells. Though the function of regulatory T cells (Tregs) in preg-
nancy has been extensively studied (5, 6), the role of regulatory B
cells in this context is still a novel field to be explored.
REGULATORY B CELLS AND THEIR EMERGING ROLE IN THE
CONTEXT OF PREGNANCY
The first reports linking suppressive activities to B cells arose from
experiments in guinea pigs, in which the transfer of B-cell-depleted
splenocytes failed to inhibit delayed-type hypersensitivity (DTH)
skin reactions (7, 8). More recently, strong evidence of the exis-
tence of B cells with suppressive capacities emerged in a murine
model of multiple sclerosis (MS) called experimental autoimmune
encephalomyelitis (EAE). In this model, mice lacking B cells suffer
an exacerbated form of the disease (9). Later on, Fillatreau et al.
showed similar results in EAE mice where the B cells are unable
to produce the anti-inflammatory cytokine, IL-10 (10). From this
point, the idea that B cells could be more than just antibody-
producing cells and could regulate the immune responses in an
IL-10-dependent fashion, started to be reinforced.
In both mouse and humans, different regulatory B-cell popula-
tions have been described. There is still controversy regarding their
phenotype, but all of them show necessarily an in vivo suppressing
capacity and their hallmark is the production of IL-10. In mice,
Evans and co-authors have described a subset of Transitional T2
B cells with CD21hiCD23+ phenotype, able to synthesize IL-10
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after stimulation of CD40 (11). Almost simultaneously, Yanaba
et al. associated a CD5+CD1d+ B-cell population with the ability
to produce IL-10 after stimulation with PMA and ionomycin, this
population was named regulatory B10 cells (12). In humans, the
phenotype is less clear. Blair and colleagues have found within the
CD19+CD24+CD38hi population, cells capable of suppressing,
through IL-10 production, the differentiation of Th1 T cells after
CD40 stimulation (13). Other authors confer the CD24hiCD27+
phenotype, which parallels the regulatory B10 cells in mouse, to
B cells with the ability to inhibit pro-inflammatory responses via
IL-10 secretion (14).
In the context of pregnancy, it was not until recently that a
role for regulatory B cells has been introduced. In a murine model
of pregnancy loss, Jensen et al. showed that CD19+CD5+CD1d+
regulatory B10 cells are diminished in the abortion-prone animals,
when compared to those with normal pregnancies. Moreover,
emulating the abortion preventing capacity of IL-10 admin-
istration (15), the transfer of IL-10-producing regulatory B10
cells was capable of reverting fetus rejection in otherwise abort-
ing animals (16). The same group found that a population of
CD19+CD24hiCD27+ regulatory B cells increases in the first
trimester of pregnancy. Interestingly, the levels of these cells in
patients suffering from spontaneous abortions remain as low as in
non-pregnant women (17).
It is not yet clear why and how these changes in regulatory B
cells during pregnancy are produced. The fact that B cells express
receptors for hormones playing a fundamental role during preg-
nancy, especially hCG and E2, highlights the importance of fur-
ther analyzing the interaction of these hormones with regulatory
B cells.
FEMALE SEX HORMONES AS MODULATORS OF REGULATORY
B CELLS ACTIVATION AND FUNCTION
As mentioned above, female sex hormones have long been sus-
pected to influence immune responses. A strong clue for a role
for female sex hormones in immunity is the fact that women are
much more susceptible to developing autoimmune diseases than
men (18, 19). In keeping with this, it is also well-documented
that the symptoms of autoimmune diseases during pregnancy,
when levels of female sex hormones are drastically modified,
are significantly affected. In this regard, women suffering from
autoimmune diseases depending on polyclonal B-cell activation
and circulating immune complexes such as systemic lupus erythe-
matosus (SLE) usually worsen during pregnancy (20, 21). How-
ever, other inflammation-driven conditions, such as rheumatoid
arthritis (RA) or MS, are reported to ameliorate (22).
The hCG is a glycoprotein hormone synthesized by the syn-
cytiotrophoblast immediately after embryo implantation. HCG
secretion is mandatory for the maintenance of the E2 and P4 pro-
duction by the corpus luteum during pregnancy until the placenta
is developed and takes over the production of these hormones (23).
Beside this fundamental role, in the past years, evidence has accu-
mulated demonstrating an immunomodulatory capacity of hCG
hormone on T cells (24–26), uNK cells (27), among others (28,
29). A recent work shifts the focus to the regulatory B cells (17).
It has been demonstrated that not only up to 95% of the
CD19+CD24hiCD27+ regulatory B cells express the receptor for
hCG (LH/hCGR) but that the addition of a human recombinant
hCG to pure isolated CD19+ B cells in vitro induced a strong
production of the potent anti-inflammatory and regulatory B-cell
hallmark, IL-10 (17).
Based on these results, the authors have proposed that hCG may
drive an expansion of IL-10-producing regulatory B cells during
normal pregnancy, thus controlling undesired immune activation
that may compromise pregnancy well-being. Indeed, B cells from
pregnant women undergoing normal pregnancies but not from
patients suffering spontaneous pregnancy loss were able to sup-
press TNF-α production, a classic pro-inflammatory cytokine, by
activated T cells (Figure 1) (17).
A very interesting phenomenon concerning the relationship
between female sex hormones and regulatory B cells is the clinical
remission that women suffering from MS experience during preg-
nancy (30). Subramanian et al. carried out a set of experiments
that led to the conclusion that sex hormones have a positive effect
on the activity of regulatory B cells that confer protection against
the symptoms of the disease. In a recent manuscript, Subramanian
and coworkers highlighted the role of regulatory B cells in the E2-
mediated protection of EAE in mice lacking Tregs (31). In those
mice, treatment with E2 provoked an augmentation of the pro-
duction of IL-10 in splenocytes and up-regulation of the negative
co-activation molecules, PDL1 and PDL2 on B cells. These results
were in concordance with previous reports in which regulatory
B cells conferred protection against EAE through production of
IL-10 (10, 32, 33).
There are two receptors that mediate the actions of E2: ER-
α and ER-β (34). It was first demonstrated that the protective
effects of E2 in EAE are mediated by ER-α (35). It is known that B
lymphocytes express ER-α and its activation affects the develop-
ment, survival, expansion, and maturation of these cells (36–38).
Recently, Bodhankar et al. showed that in the context of EAE, E2
acts in an ER-α-dependent way through B cells and not T cells.
Notably, these protective effects of E2 are lost in the absence of B
cells (39).
The scenario presented here centers on the regulatory B cells
that, as a consequence of the higher levels of E2 in pregnancy,
launch a set of suppressive mechanisms (IL-10 production, expres-
sion of PDL1) that favors immune tolerance (Figure 1). This
probable natural necessity in pregnancy may be one reason for the
clinical improvement observed in women with MS during gravity.
The steroid hormone progesterone is essential for the implan-
tation as well as for the development of an adequate uterine
structure, which involves changes in the growth and differenti-
ation of the epithelial and stromal cell layers of the endometrial
compartment that enables the maintenance of pregnancy (40).
Several studies have established the importance of this hormone
influencing the activity of various types of immune cells, such
as the ability to inhibit the presenting capacity of dendritic cells
(DCs) (41), monocytes, and macrophages (42, 43). Progesterone
also has an impact on the levels of galectin-1, which in turn
promotes the expansion and recruitment of suppressive uterine
DCs (44).
An immunomodulatory action of P4 on B cells has also been
described (45, 46). Treatment with P4 reduces the severity of EAE,
elevating the levels of IL-10 and the numbers of CD19+ cells (47)
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FIGURE 1 | Schematic representation depicting the influence of
female sex hormones in the activation and subsequent function of
regulatory B cells (Bregs). (A) Estradiol (E2), acting through estradiol
receptor alpha (ERα), induces the proliferation as well as the production
of IL-10 by regulatory B cells (Breg). In addition, E2 mediates the control
of T cells’ activation by B cells throughout a mechanism involving
PDL1/PD1 pathway. (B) Human chorionic gonadotropin (hCG) was
proposed to induce proliferation of regulatory B cells. Besides, this
hormone induces the production of IL-10 by B cells that in turn inhibit the
production of TNFα by T cells. (C) Progesterone (P4) induces the
production of the potent anti-inflammatory and Breg hallmark cytokine
IL-10 by B cells.
(Figure 1). This work invites us to speculate, that as for hCG
and E2, P4 could have an immunomodulatory action on regu-
latory B cells that may play a beneficial role in the remission of
MS during gravity and the phenomenon of regulated tolerance in
pregnancy.
CONCLUSION
We describe in this review a B-cell subset capable of being activated
and expanded upon hormone treatment, with the ability to sup-
press pro-inflammatory responses, leading to protection against
EAE or pregnancy loss. Many therapeutic approaches for the treat-
ment of autoimmune disease are centered on the depletion of B
cells. Therefore, unspecific deletion of B cells as in the case of Rit-
uximab™ treatment in MS patients (48) may result in the loss
of a potentially valuable subset of B cells that mediate a benefi-
cial anti-inflammatory environment associated with the transient
remission of the disease. A better understanding of the mecha-
nisms behind the activation and expansion of this population of
regulatory B cells can provide novel therapeutic strategies against
autoimmune diseases like MS as well as to pregnancy-associated
disturbances.
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